Medical, Science & Research

52 terms in this category

Addiction ⚠️

Compulsive substance use despite harm — approximately 9% of cannabis users develop CUD

Amyotrophic Lateral Sclerosis — a qualifying condition in most medical cannabis states

Pain-relieving substance — cannabis has substantial evidence for chronic pain relief

A substance that prevents or reduces nausea and vomiting — cannabis has conclusive evidence for CINV

Anti-inflammatory

Reducing inflammation — cannabinoids act through CB2 and non-cannabinoid receptor pathways

Seizure-reducing agent — CBD is FDA-approved for Dravet and Lennox-Gastaut syndromes

Anxiolytic (clinical)

An agent that reduces anxiety — CBD shows consistent anxiolytic effects in lab paradigms

Appetite stimulant

An agent that increases appetite — THC is FDA-approved for AIDS-related anorexia (dronabinol)

Severe wasting syndrome in chronic illness — dronabinol is FDA-approved for AIDS cachexia

Cannabis Use Disorder

DSM-5 diagnosis for problematic cannabis use — affects approximately 9% of users

Canadian cannabis company backed by Constellation Brands — once the industry's largest by market cap

Persistent pain lasting >3 months — substantial evidence supports cannabinoid treatment

Cannabinoid Hyperemesis Syndrome — cyclical vomiting in heavy users, relieved by hot showers

Chemotherapy-Induced Nausea and Vomiting — cannabis has conclusive evidence for treatment

Cochrane review

Systematic reviews by the Cochrane Collaboration — considered the gold standard in evidence-based medicine

Compassionate use

Programs providing experimental drugs to seriously ill patients outside clinical trials

Crohn's disease

Inflammatory bowel disease — limited evidence for cannabis benefit, mostly symptom relief

Physiological adaptation requiring continued use to avoid withdrawal symptoms

Neither researcher nor participant knows who receives active drug — the gold standard

Dr. Donald Abrams

UCSF oncologist who conducted early clinical cannabis trials for AIDS wasting and pain

Dr. Ethan Russo

Neurologist who formalized the entourage effect and terpene-cannabinoid interaction hypothesis

Dr. Raphael Mechoulam

Israeli chemist who isolated THC (1964) and discovered anandamide (1992) — father of cannabinoid research

Researcher conducting FDA-approved clinical trials of cannabis for PTSD in veterans

Dr. Yasmin Hurd

Mount Sinai neuroscientist researching CBD for opioid addiction and substance use disorders

Dravet syndrome

Severe childhood epilepsy — Epidiolex approval indication, Charlotte Figi's condition

Synthetic THC — FDA-approved 1985 for CINV and AIDS anorexia (brand: Marinol)

Purified plant-derived CBD — FDA-approved 2018 for Dravet and Lennox-Gastaut syndromes

Seizure disorder — CBD (Epidiolex) is the only FDA-approved plant-derived cannabinoid drug

Chronic widespread pain condition — limited but growing evidence for cannabis benefit

GW Pharmaceuticals

UK company that developed Epidiolex and Sativex — acquired by Jazz Pharmaceuticals 2021

Inflammatory bowel disease

Umbrella term for Crohn's and ulcerative colitis — preclinical data for cannabinoid therapy

Institutional Review Board — ethics committee that must approve human cannabis research

Israel (cannabis research)

Global leader in cannabis research — Mechoulam's home base, 30,000+ medical patients

Lennox-Gastaut syndrome

Severe childhood epilepsy — second FDA-approved Epidiolex indication

Brand name for dronabinol — synthetic THC capsules, Schedule III since 1999

Medical marijuana

Cannabis used therapeutically under state authorization — distinct from FDA-approved drugs

Statistical synthesis of results from multiple studies — the highest tier of evidence

MS (Multiple Sclerosis)

Autoimmune neurological disease — Sativex is approved for MS spasticity in 25+ countries

Synthetic cannabinoid — FDA-approved 1985 for CINV (brand: Cesamet)

National Academies of Sciences report (2017) — the definitive evidence review for cannabis therapeutics

Neuropathic pain

Pain from nerve damage — cannabis shows moderate-to-substantial evidence for relief

Neuroprotective

Protecting neurons from damage — cannabinoids show preclinical neuroprotective activity

National Institute on Drug Abuse — historically the sole supplier of research-grade cannabis

NIH cannabis research

Federal cannabis research infrastructure — historically restricted by Schedule I barriers

Using an approved drug for an unapproved indication — common with dronabinol and nabilone

Placebo-controlled

Study design comparing active drug to inactive placebo — challenged by cannabis's obvious effects

Post-Traumatic Stress Disorder — a qualifying condition in most medical cannabis states

THC:CBD oromucosal spray — approved in 25+ countries for MS spasticity, not FDA-approved

Systematic review

Methodical survey of all published research on a specific question

Canadian cannabis company — merged with Aphria 2021, now Tilray Brands

Tolerance (clinical)

Diminished pharmacological response requiring increased dose — CB1 receptor downregulation

Symptoms upon cannabis cessation — irritability, insomnia, appetite loss, anxiety

Other Categories

Botany & Cultivation

Chemistry, Cannabinoids & ECS

Flower, Hash & Concentrates

Edibles, Smokeware & Devices

Consumption, Effects & Measurement

Legal & Regulatory

Industry & Commerce

Slang, Culture & History